# Coherus Oncology Shares Tagmokitug Trial Results

> Coherus Oncology reveals interim tagmokitug clinical data for esophageal cancer treatment.
- Title: Coherus Oncology Shares Tagmokitug Trial Results | Shortify
- Summary: Coherus Oncology reveals interim tagmokitug clinical data for esophageal cancer treatment. Coherus Oncology presented interim clinical data showing…
- Keywords: coherus oncology, tagmokitug, esophageal cancer, clinical data, interim results, oncology, money, business, Coherus, Shares, Trial, Results
- Source: Seekingalpha — https://seekingalpha.com/article/4959035-coherus-oncology-inc-chrs-discusses-tagmokitug-interim-clinical-data-in-esophageal-cancer
- Author: SA Transcripts
- Published: 2026-10-29T10:58:32+00:00
- Read time: 1 min
- Topics: coherus oncology, tagmokitug, esophageal cancer, clinical data, interim results, oncology, money, business
## Coherus Oncology
Coherus Oncology, Inc. (CHRS) discussed interim clinical data for tagmokitug in esophageal cancer.
## Interim Clinical Data
The company shared interim results from tagmokitug trials targeting esophageal cancer treatment.
## Clinical Presentation
Dennis Lanfear presented tagmokitug's potential in esophageal cancer with interim data.
## Key takeaway

Coherus Oncology presented interim clinical data showing tagmokitug's potential in esophageal cancer treatment.